Gräslund T

Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts.

Zhang J, Rinne SS, Yin W, ..., Gräslund T, Vorobyeva A

ACS pharmacology & translational science 7 (10) 3228-3240 [2024-10-11; online 2024-09-12]

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules.

Rinne SS, Yin W, Borras AM, ..., Orlova A, Gräslund T

Biomedicines 10 (6) - [2022-05-31; online 2022-05-31]

Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis.

Bronge M, Högelin KA, Thomas OG, ..., Olsson T, Grönlund H

Sci Adv 8 (17) eabn1823 [2022-04-29; online 2022-04-27]

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy.

Yin W, Xu T, Altai M, ..., Gräslund T, Orlova A

Pharmaceutics 13 (11) - [2021-11-21; online 2021-11-21]

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.

Xu T, Vorobyeva A, Schulga A, ..., Tolmachev V, Deyev SM

Cancers (Basel) 13 (16) - [2021-08-04; online 2021-08-04]

Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1.

Deyev SM, Xu T, Liu Y, ..., Tolmachev V, Vorobyeva A

Cancers (Basel) 13 (14) - [2021-07-17; online 2021-07-17]